Kazia Therapeutics (KZIA) Other Non-Current Liabilities (2009 - 2025)

Kazia Therapeutics (KZIA) has 17 years of Other Non-Current Liabilities data on file, last reported at $6.3 million in Q4 2025.

• Quarterly Other Non-Current Liabilities fell 7.39% year-over-year to $6.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.3 million (down 7.39% YoY) and the FY2025 annual result came in at $6.5 million, down 34.75% from the prior year.
• Other Non-Current Liabilities declined to $6.3 million in Q4 2025, from $6.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $9.9 million in Q2 2024 to a low of $2.1 million in Q4 2022.
• A 5-year average of $5.0 million and a median of $4.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 56.58% — and 2024, when it surged 243.21%.
• Tracing KZIA's Other Non-Current Liabilities over 5 years: stood at $4.8 million in 2021, then slumped by 56.58% to $2.1 million in 2022, then jumped by 88.38% to $3.9 million in 2023, then soared by 75.51% to $6.8 million in 2024, then decreased by 7.39% to $6.3 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $6.3 million (Q4 2025), $6.5 million (Q2 2025), and $6.8 million (Q4 2024), per Business Quant data.